New oral pill for COVID-19 home treatment

The continued emergence of novel and potentially threatened SARS-CoV-2 variants, the latest of which is the highly pathogenic Omicron variant (VOC), is evidence that the coronavirus 2019 (COVID-19) pandemic is far from over, although The massive spread of vaccines. As cases and hospitalizations continue to rise in many countries, new treatments are being sought to … Read more

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a synthetic short chain of chemically modified nucleotides engineered at the Institute of RNA Therapeutics at UMass Chan School of Medicine, Robert H. The ALS gene known as C9ORF72 in a pilot study of a single patient. C9ORF72 is the most common cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). … Read more

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The novel coronavirus 2019 (COVID-19) pandemic was caused by a new coronavirus, i.e., severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The RNA virus causes mild to severe symptoms and has a high transmission rate. In severe infection, patients often have a highly inflammatory response, which has been associated with morbidity and mortality due to COVID-19 disease. … Read more

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc. has announced. , a biotech company that is a leading biotech company in mRNA therapies and vaccines, today announced that the first participant underwent doses in a phase 1 study of mRNA-1189, the company’s Epstein-Barr virus (EBV) vaccine candidate. The study is known as an eclipse. “EBV is one of the most common … Read more